Question Bank › Named catch-up gap

Named catch-up gap

Named catch-up gap: management identifies where the company visibly lags peers or its own potential, and is already clos

Calls Tested
500
Answered YES
24
Hit Rate
4.8%
rare by design

Zimmer Biomet Holdings, Inc. (ZBH) — this company's answers

NO on the Q2 2017 call 2017-07-30 F
The model's full reasoning — Q2 2017 call → NO我们根据提供的财报电话会议记录，判断管理层是否明确指出了公司当前在某个具体维度上表现不佳（相对于行业同行、行业规范或公司自身在其他业务中展现的潜力），并描述了已经进行中的工作来缩小这一差距，且管理层将缩小差距视为有意义的改进来源，不依赖于市场条件改善。 在记录中，管理层多次提到生产问题、供应链问题、客户流失等。具体来说，他们提到了“production delays within certain key brands”、“sales recapture from previously affected customers in the United States was impacted by our delayed production output”等。他们承认了这些问题，并描述了正在进行的修复工作，例如“we delivered production consistency with significantly less disruption than we saw in the first quarter”、“we expect to continue building safety stock of these products through the third quarter”等。他们还提到了“we are revising our 2017 sales and earnings guidance”等。 然而，问题要求的是“IDENTIFY A SPECIFIC, NAMED DIMENSION ON WHICH THE COMPANY CURRENTLY UNDERPERFORMS — relative to industry peers, industry norms, or the company's own demonstrated potential elsewhere in its business”。管理层是否明确指出了具体维度？他们提到了“production delays”、“supply shortfalls”、“back orders”等，但这是否是相对于同行或自身潜力的具体差距？他们提到了“our continued strong growth in the Asia-Pacific region”与“our sales in the Europe, Middle East and Africa region decreased”的对比，但这是否是明确指出的差距？他们提到了“we delivered the highest quarterly output on record from our Warsaw North Campus manufacturing facility”但“reaching full production of certain brands has proven to be more challenging than initially anticipated”。这似乎是在承认生产问题，但并没有明确说相对于同行或自身潜力，公司在某个具体维度上落后。 此外，他们提到了“pricing pressure of 2.6%”等，但这是否是具体差距？他们提到了“negative price of 2.8%”等，但并没有明确说这是相对于同行或自身潜力的差距。 问题还要求“describe work ALREADY UNDERWAY to close that specific gap”，管理层确实描述了正在进行的修复工作，例如“we continue to make progress meaningfully reducing back orders”、“we expect to continue building safety stock”等。但这是否是针对一个“specific, named dimension”？ 我认为管理层承认了生产供应问题，但并没有明确将其定义为相对于同行或自身潜力的具体差距。他们更多是描述问题本身，而不是将其与基准比较。此外，他们也没有明确说这个差距是可以通过自身努力关闭的，尽管他们提到了“we expect to reach sufficient safety stock levels across our entire portfolio as we exit 2017”，但这是否是“meaningful source of improvement”？ 在记录中，管理层说“we are revising our 2017 sales and earnings guidance”，并提到了“incremental manufacturing costs”等。但整体上，他们并没有明确说“我们在这个维度上落后于同行”或“我们在这个维度上不如我们自己的其他业务”。 因此，我认为答案应为NO。

← Back to the full ZBH analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management IDENTIFY A SPECIFIC, NAMED DIMENSION ON WHICH THE COMPANY CURRENTLY UNDERPERFORMS — relative to industry peers, industry norms, or the company's own demonstrated potential elsewhere in its business — AND describe work ALREADY UNDERWAY to close that specific gap, with management treating the closing of it as a meaningful source of improvement that does not depend on market conditions getting better? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent self-diagnosis with both halves present: (1) A NAMED GAP, OWNED BY MANAGEMENT: management itself states, concretely, where the company lags — for example margins, productivity, utilization, pricing, mix, service levels, penetration of its own customer base, or performance of one region, segment, or facility versus the company's own better ones or versus what peers demonstrably achieve — identified specifically enough that a reader knows exactly what is deficient and roughly how large the shortfall is; and (2) CLOSING WORK IN MOTION WITH THE MECHANISM EXPLAINED: management describes the concrete actions already executing to close it — not aspirations — and conveys why the gap is closable by the company's own effort (the better level is already achieved by peers or by the company's own best operations, so the target is demonstrated rather than theoretical), with early progress or a credible operational path visible in the current period. Answer NO if management only claims general improvement opportunity without naming a specific measurable gap. NO if the gap is blamed on external conditions that must improve. NO if the closing work is only planned, promised, or under study. NO if the gap-closing is ordinary cost-cutting rhetoric with no named benchmark. NO if the diagnosis appears only in an analyst's question that management does not itself adopt. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
ASO Academy Sports and Outdoors, Inc. Q1 2024 2024-06-11 C+
MEG Montrose Environmental Group, Inc. Q3 2023 2023-11-08 C+
RVLV Revolve Group, Inc. Q3 2023 2023-11-01 C
CMG Chipotle Mexican Grill, Inc. Q3 2023 2023-10-27 B+
SWK Stanley Black & Decker, Inc. Q1 2023 2023-05-04 D
TMCI Treace Medical Concepts, Inc. Q2 2022 2022-08-13 B+
STC Stewart Information Services Corporation Q1 2022 2022-04-29 C+
KD Kyndryl Holdings, Inc. Q4 2021 2022-03-01 C+
FLUX Flux Power Holdings, Inc. Q2 2022 2022-02-10 D
HNRG Hallador Energy Company Q3 2021 2021-11-09 C+
LPTH LightPath Technologies, Inc. Q4 2021 2021-09-09 D
KOP Koppers Holdings Inc. Q2 2018 2018-08-12 C+
MKC McCormick & Company, Incorporated Q2 2018 2018-06-28 C+
ACHC Acadia Healthcare Company, Inc. Q4 2017 2018-02-22 C+
ADNT Adient plc Q1 2018 2018-01-29 D
HOLX Hologic, Inc. Q4 2017 2017-11-08 D
STKL SunOpta Inc. Q2 2017 2017-08-09 C+
PTC PTC Inc. Q3 2017 2017-07-19 C+
ABM ABM Industries Incorporated Q2 2017 2017-06-08 B
PPG PPG Industries, Inc. Q1 2017 2017-04-20 C
PDCO Patterson Companies, Inc. Q3 2017 2017-02-23 C
SXT Sensient Technologies Corporation Q4 2016 2017-02-10 A
BC Brunswick Corporation Q3 2016 2016-10-28 B+
SON Sonoco Products Company Q4 2015 2016-02-11 B

How the model reasoned

HOLX · Q4 2017 → YESThe question is: Does management identify a specific, named dimension on which the company currently underperforms — relative to industry peers, industry norms, or the company's own demonstrated poten...YES The transcript shows management explicitly diagnosing Cynosure’s commercial organization as the specific underperforming dimension (salesforce turnover, recruiting, and productivity lagging behind the company’s international business and its own best operations). They then describe concrete, already-executing actions—stopping voluntary turnover, rehiring high performers, instituting 90-day reviews, new compensation, and building “Cynosure 2.0”—as the mechanism to close the gap.
STKL · Q2 2017 → YESThe question is: Does management identify a specific, named dimension on which the company currently underperforms — relative to industry peers, industry norms, or the company's own demonstrated poten...YES The transcript shows management identifying a specific named gap in the bars segment, where operational issues at a particular facility are causing inefficient production and gross margin losses. They describe a rapid recovery team already executing systematic identification and correction of these issues, treating the gap as closable through their own operational efforts rather than external market improvements — this aligns with the criteria for a meaningful source of improvement.
ADNT · Q1 2018 → YESThe question is: Does management identify a specific, named dimension on which the company currently underperforms — relative to industry peers, industry norms, or the company's own demonstrated poten...YES The transcript shows management explicitly naming the Seat Structures and Mechanisms (SS&M) business as the specific underperforming dimension. They state it is “destroyed shareholder value” when run as currently organized, and that it is “impacting our financial results” with “significant impact.

More from the question bank

Paid to expand: the company's growth spendinThe product is disappearing into reorder rhyRecently unlocked doorWorking for customers it could not have servVolume records through a still-fixed gateTwo-sided intensityAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.